2023 Department of Pediatrics Academic Annual Report

GRANTS AWARDED IN 2023

INVESTIGATOR PROJECT TITLE

SPONSOR

DIRECT AWARDED

Whitley, Richard J.

Antiviral Drug Discovery and Development Center (AD3C)

National Institute of Allergy and Infectious Diseases/NIH/DHHS

$7,371,090

Kimberlin, David Winston

Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)

National Institute of Allergy and Infectious Diseases/NIH/DHHS

$1,136,832

Kimberlin, David Winston

Burden of Neonatal Herpes Simplex Virus Infections: Disease Incidence, Adequacy of Diagnostic Assessment, Disease Outcome, and Societal Costs

National Institute of Allergy and Infectious Diseases/NIH/DHHS

$974,299

Boppana, Suresh B.

Adaptive Immunity and Persistent SARS CoV-2 Replication

National Cancer Institute/NIH/ DHHS

$509,126

Kimberlin, David Winston

A Phase II, Single-Stage, Single Arm Investigation of Oral Valganciclovir Therapy in Infants with Asymptomatic Congenital Cytomegalovirus Infection

National Institute of Allergy and Infectious Diseases/NIH/DHHS

$460,731

Poole, Claudette

Ryan White Part B UAB Family Clinic

United Way of Central Alabama, Inc.

$401,717

Fowler, Karen B.

Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus in Pregnancy

National Institute of Child Health and Human Development/NIH/ DHHS

$400,110

Britt, William J.

CMV Vaccines: Reinfection and Antigenic Variation

Harvard College

$398,052

Poole, Claudette

Reducing The Burden of Soil Transmitted Helminth Infection in At-Risk Communities in Rural Alabama Through Evidence-Based Prevention and Control Activities

Centers for Disease Control and Prevention (CDC)/DHHS

$357,143

James, Scott H.

In Vitro Assessments of Antimicrobial Activity Task Area B Comprehensive Viral Screening Panel—In Vitro Assessment for Antimicrobial Activity Task Order B21 Comprehensive Viral Screening Panel

NIH - National Institutes of Health/DHHS

$281,539

Boppana, Suresh B.

A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate in Healthy Children

Pfizer Inc., U.S. Pharmaceuticals Group

$216,097

2023 Academic Annual Report

95